ArticleClinicoEconomics and outcomes research : CEOR2015

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective.

Stephane A Régnier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.